18F-FET PET for planning of thermotherapy using magnetic nanoparticles in recurrent glioblastoma

International Journal of Hyperthermia

Volumn 22, Issue 4, 2006, Pages 319-325

  Plotkin, Michail ^a   Gneveckow, Uwe ^b   Meier Hauff, Klaus ^c   Amthauer, Holger ^a   Feußner, Annelie ^a   Denecke, Timm ^a   Gutberlet, Matthias ^a   Jordan, Andreas ^b   Felix, Roland ^a   Wust, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MagForce Nanotechnologies AG   (Germany)

^c Bundeswehrkrankenhaus Berlin ^*  (Germany)

Author keywords

18F FET; Nano cancer therapy; Positron emission topography; Recurrent glioblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORINE 18; NANOPARTICLE; O (2 FLUOROETHYL)TYROSINE; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; NANOMATERIAL; O-(2-FLUOROETHYL)TYROSINE; TYROSINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTHERMIC THERAPY; INTERMETHOD COMPARISON; MALE; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; BRAIN TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; MAGNETISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC RESONANCE IMAGING; MAGNETICS; MALE; MIDDLE AGED; NANOSTRUCTURES; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TYROSINE;

EID: 33745082768     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730600734128     Document Type: Article

References (24)

1. Jordan, A and Scholz, R and Wust, P and Fahling, H and Krause, J and Wlodarczyk, W and Sander, B and Vogl, T and Felix, R. (1997) Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo Int J Hyperthermia, 13, pp. 587-605.
2. Jordan, A and Wust, P and Scholz, R and Tesche, B and Fahling, H and Mitrovics, T and Vogl, T and Cervos-Navarro, J and Felix, R. (1996) Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro Int J Hyperthermia, 12, pp. 705-722.
3. Gneveckow, U and Jordan, A and Scholz, R and Bruess, V and Waldoefner, N and Ricke, J and Feussner, A and Hildebrandt, B and Rau, B and Wust, P. (2004) Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia Med Phys, 31, pp. 1444-1451.
4. Jordan, A and Scholz, R and Maier-Hauff, K and van Landeghem, FK and Waldoefner, N and Teichgraeber, U and Pinkernelle, J and Bruhn, H and Neumann, F and Thiesen, B and von Deimling, A and Felix, R. (2005) The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma J Neurooncol, 29, pp. 1-8.
5. Johannsen, M and Jordan, A and Scholz, R and Koch, M and Lein, M and Deger, S and Roigas, J and Jung, K and Loening, S. (2004) Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer J Endourol, 18, pp. 495-500.
6. Johannsen, M and Thiesen, B and Jordan, A and Taymoorian, K and Gneveckow, U and Waldoefner, N and Scholz, R and Koch, M and Lein, M and Jung, K and Loening, SA. (2005) Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model Prostate, 64, pp. 283-292.
7. Johannsen, M and Thiesen, B and Gneveckow, U and Taymoorian, K and Waldoefner, N and Scholz, R and Deger, S and Jung, K and Loening, SA and Jordan, A. (2006) Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer Prostate, 66, pp. 97-104.
8. Johannsen, M and Gneveckow, U and Eckelt, L and Feussner, A and Waldoefner, N and Scholz, R and Deger, S and Wust, P and Loening, SA and Jordan, A. (2005) Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique Int J Hyperthermia, 21, pp. 637-647.
9. Leeds, NE and Jackson, EF. (1994) Current imaging techniques for the evaluation of brain neoplasms Curr Opin Oncol, 6, pp. 254-261.
10. Kelly, PJ and Daumas-Duport, C and Scheithauer, BW and Kall, BA and Kispert, DB. (1987) Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms Mayo Clin Proc, 62, pp. 450-459.
11. Samnick, S and Bader, JB and Hellwig, D and Moringlane, JR and Alexander, C and Romeike, BF and Feiden, W and Kirsch, CM. (2002) Clinical value of iodine-alpha-methyl-]L-thyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up J Clin Oncol, 20, pp. 396-404.
12. Kuwert, T and Woesler, B and Morgenroth, C and Lerch, H and Schafers, M and Palkovic, S and Matheja, P and Brandau, W and Wassmann, H and Schober, O. (1998) Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine J Nucl Med, 39, pp. 23-27.
13. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 Tesla in the differential diagnosis of recurrent or residual gliomas: A comparative study J Neuro Oncol, 70, pp. 49-58.
14. 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours Neuroradiology, 47, pp. 18-26.
15. 123I-IMT scans in patients with suspected recurrent or residual brain tumors Clin Nucl Med, 31, pp. 189-192.
16. 18 F]fuoroethyl)-]L-tyrosine PET for the diagnosis of recurrent glioma Eur J Nucl Med Mol Imag, 11, pp. 1464-1470.
17. Grosu, AL and Feldmann, H and Dick, S and Dzewas, B and Nieder, C and Gumprecht, H and Frank, A and Schwaiger, M and Molls, M and Weber, WA. (2002) Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas Int J Radiat Oncol Biol Phys, 54, pp. 842-854.
18. 11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy Int J Radiat Oncol Biol Phys, 63, pp. 64-74.
19. Nuutinen, J and Sonninen, P and Lehikoinen, P and Sutinen, E and Valavaara, R and Eronen, E and Norrgard, S and Kulmala, J and Teras, M and Minn, H. (2000) Radiotherapy treatment planning and long-term follow-up with [(11)C] methionine PET in patients with low-grade astrocytoma Int J Radiat Oncol Biol Phys, 48, pp. 43-52.
20. Grosu, AL and Weber, WA and Franz, M and Stark, S and Piert, M and Thamm, R and Gumprecht, H and Schwaiger, M and Molls, M and Nieder, C. (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy Int J Radiat Oncol Biol Phys, 63, pp. 511-519.
21. 11C]L-methionine positron emission tomography: Local comparison with stereotactic histopathology Clin Cancer Res, 10, pp. 7163-7170.
22. 18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas Brain, 128, pp. 678-687.
23. 11 C] methionine uptake in brain tumours: Initial results of a comparative study Eur J Nucl Med, 27, pp. 542-549.
24. 18F-fluoroethyl)-L-tyrosinePET and 3-123I-iodo-α-methyl-L-tyrosine SPECT in brain tumors J Nucl Med, 45, pp. 374-381.